A novel synthetic bipartite carrier protein for developing glycotope-based vaccines

Hsiao Ling Chiang, Chi Yu Lin, Fan Dan Jan, Yaoh Shiang Lin, Chia Tse Hsu, Jacqueline Whang-Peng, Leroy F. Liu, Shin Nieh, Chun Cheng Lin, Jaulang Hwang

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Development of successful vaccines against glycotopes remains a major challenge. In the current studies, we have successfully developed a novel carrier protein for glycotopes based on the concept of antigen clustering and specific stimulation of T helper cells to mount strong antibody response to glycotopes. The bipartite carrier protein consists of a tandem repeat of a cysteine-rich peptide for docking of clustered glycotopes to effectively activate B cells and an Fc domain for antigen delivery to antigen presenting cells (APCs). To demonstrate its utility, we conjugated the tumor-specific monosaccharide antigen Tn to this novel carrier protein and successfully developed a Tn vaccine against cancer in animal models. The Tn vaccine effectively elicited high-titer IgG1 antibodies against Tn in immunized mice, and effectively suppressed the development of prostate cancer in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice. Our results suggest that this novel bipartite carrier protein could be effectively used for developing anti-glycotope vaccines such as the anticancer Tn vaccine.

Original languageEnglish
Pages (from-to)7573-7581
Number of pages9
JournalVaccine
Volume30
Issue number52
DOIs
Publication statusPublished - Dec 14 2012

Fingerprint

transport proteins
Carrier Proteins
Vaccines
vaccines
antigens
mice
Antigens
Cancer Vaccines
Tandem Repeat Sequences
neoplasms
antibodies
tandem repeat sequences
antigen-presenting cells
Monosaccharides
vaccine development
prostatic neoplasms
Antigen-Presenting Cells
monosaccharides
Helper-Inducer T-Lymphocytes
adenocarcinoma

Keywords

  • Carrier protein
  • Glycotope
  • Tn antigen
  • Tumor immunotherapy
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Chiang, H. L., Lin, C. Y., Jan, F. D., Lin, Y. S., Hsu, C. T., Whang-Peng, J., ... Hwang, J. (2012). A novel synthetic bipartite carrier protein for developing glycotope-based vaccines. Vaccine, 30(52), 7573-7581. https://doi.org/10.1016/j.vaccine.2012.10.041

A novel synthetic bipartite carrier protein for developing glycotope-based vaccines. / Chiang, Hsiao Ling; Lin, Chi Yu; Jan, Fan Dan; Lin, Yaoh Shiang; Hsu, Chia Tse; Whang-Peng, Jacqueline; Liu, Leroy F.; Nieh, Shin; Lin, Chun Cheng; Hwang, Jaulang.

In: Vaccine, Vol. 30, No. 52, 14.12.2012, p. 7573-7581.

Research output: Contribution to journalArticle

Chiang, HL, Lin, CY, Jan, FD, Lin, YS, Hsu, CT, Whang-Peng, J, Liu, LF, Nieh, S, Lin, CC & Hwang, J 2012, 'A novel synthetic bipartite carrier protein for developing glycotope-based vaccines', Vaccine, vol. 30, no. 52, pp. 7573-7581. https://doi.org/10.1016/j.vaccine.2012.10.041
Chiang, Hsiao Ling ; Lin, Chi Yu ; Jan, Fan Dan ; Lin, Yaoh Shiang ; Hsu, Chia Tse ; Whang-Peng, Jacqueline ; Liu, Leroy F. ; Nieh, Shin ; Lin, Chun Cheng ; Hwang, Jaulang. / A novel synthetic bipartite carrier protein for developing glycotope-based vaccines. In: Vaccine. 2012 ; Vol. 30, No. 52. pp. 7573-7581.
@article{57b03dbfd194463eb658b764af99b367,
title = "A novel synthetic bipartite carrier protein for developing glycotope-based vaccines",
abstract = "Development of successful vaccines against glycotopes remains a major challenge. In the current studies, we have successfully developed a novel carrier protein for glycotopes based on the concept of antigen clustering and specific stimulation of T helper cells to mount strong antibody response to glycotopes. The bipartite carrier protein consists of a tandem repeat of a cysteine-rich peptide for docking of clustered glycotopes to effectively activate B cells and an Fc domain for antigen delivery to antigen presenting cells (APCs). To demonstrate its utility, we conjugated the tumor-specific monosaccharide antigen Tn to this novel carrier protein and successfully developed a Tn vaccine against cancer in animal models. The Tn vaccine effectively elicited high-titer IgG1 antibodies against Tn in immunized mice, and effectively suppressed the development of prostate cancer in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice. Our results suggest that this novel bipartite carrier protein could be effectively used for developing anti-glycotope vaccines such as the anticancer Tn vaccine.",
keywords = "Carrier protein, Glycotope, Tn antigen, Tumor immunotherapy, Vaccine",
author = "Chiang, {Hsiao Ling} and Lin, {Chi Yu} and Jan, {Fan Dan} and Lin, {Yaoh Shiang} and Hsu, {Chia Tse} and Jacqueline Whang-Peng and Liu, {Leroy F.} and Shin Nieh and Lin, {Chun Cheng} and Jaulang Hwang",
year = "2012",
month = "12",
day = "14",
doi = "10.1016/j.vaccine.2012.10.041",
language = "English",
volume = "30",
pages = "7573--7581",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "52",

}

TY - JOUR

T1 - A novel synthetic bipartite carrier protein for developing glycotope-based vaccines

AU - Chiang, Hsiao Ling

AU - Lin, Chi Yu

AU - Jan, Fan Dan

AU - Lin, Yaoh Shiang

AU - Hsu, Chia Tse

AU - Whang-Peng, Jacqueline

AU - Liu, Leroy F.

AU - Nieh, Shin

AU - Lin, Chun Cheng

AU - Hwang, Jaulang

PY - 2012/12/14

Y1 - 2012/12/14

N2 - Development of successful vaccines against glycotopes remains a major challenge. In the current studies, we have successfully developed a novel carrier protein for glycotopes based on the concept of antigen clustering and specific stimulation of T helper cells to mount strong antibody response to glycotopes. The bipartite carrier protein consists of a tandem repeat of a cysteine-rich peptide for docking of clustered glycotopes to effectively activate B cells and an Fc domain for antigen delivery to antigen presenting cells (APCs). To demonstrate its utility, we conjugated the tumor-specific monosaccharide antigen Tn to this novel carrier protein and successfully developed a Tn vaccine against cancer in animal models. The Tn vaccine effectively elicited high-titer IgG1 antibodies against Tn in immunized mice, and effectively suppressed the development of prostate cancer in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice. Our results suggest that this novel bipartite carrier protein could be effectively used for developing anti-glycotope vaccines such as the anticancer Tn vaccine.

AB - Development of successful vaccines against glycotopes remains a major challenge. In the current studies, we have successfully developed a novel carrier protein for glycotopes based on the concept of antigen clustering and specific stimulation of T helper cells to mount strong antibody response to glycotopes. The bipartite carrier protein consists of a tandem repeat of a cysteine-rich peptide for docking of clustered glycotopes to effectively activate B cells and an Fc domain for antigen delivery to antigen presenting cells (APCs). To demonstrate its utility, we conjugated the tumor-specific monosaccharide antigen Tn to this novel carrier protein and successfully developed a Tn vaccine against cancer in animal models. The Tn vaccine effectively elicited high-titer IgG1 antibodies against Tn in immunized mice, and effectively suppressed the development of prostate cancer in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice. Our results suggest that this novel bipartite carrier protein could be effectively used for developing anti-glycotope vaccines such as the anticancer Tn vaccine.

KW - Carrier protein

KW - Glycotope

KW - Tn antigen

KW - Tumor immunotherapy

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84870516343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870516343&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2012.10.041

DO - 10.1016/j.vaccine.2012.10.041

M3 - Article

C2 - 23099332

AN - SCOPUS:84870516343

VL - 30

SP - 7573

EP - 7581

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 52

ER -